Current and Emerging Therapies in the Management of Hypoxic Ischemic Encephalopathy in Neonates.

ABSTRACT: Neonatal hypoxic ischemic encephalopathy (HIE) presents a significant clinical burden with its high mortality and morbidity rates globally. Therapeutic hypothermia (TH) is now standard of care for infants with moderate to severe HIE, but has not definitively changed outcomes in severe HIE. In this review, we discuss newer promising markers that may help the clinician identify severity of HIE. Therapies that are beneficial and agents that hold promise for neuroprotection are described, both for use either alone or as adjuncts to TH. These include endogenous pathway modifiers such as erythropoietin and analogues, melatonin, and remote ischemic post conditioning. Stem cells have therapeutic potential in this condition, as in many other neonatal conditions. Of the agents listed, only erythropo

SUBMITTER: Nair J 

PROVIDER: S-EPMC6069156 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature